SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The broader market ended slightly lower on Thursday, unable to sustain its recovery from Wednesday's slump triggered by the Federal Reserve's December rate-setting meeting. Defensive sectors such as real estate, healthcare, consumer staples, and material and energy stocks served as drags.&nbsp;On a positive note, the Dow Industrials snapped a 10-session losing streak thanks to stock-specific strength.Amid Thursday’s lackluster market performance, the following technology and communication services stocks saw the loudest retail chatter:Angi, Inc. ($ANGI)Denver, Colorado-based Angi, which connects home service professionals with consumers, saw its stock rally by 3.66% on Thursday despite a lack of news. The stock rally set the retail crowd chatting, sending message volume up by 1,500%.On Stocktwits, sentiment toward the stock stayed ‘extremely bullish’ (97/100), with message volume also at ‘extremely high’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:642/141;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/angi_sentiment_1b5675d3c5.png" alt="angi-sentiment.png" width="642" height="141"><figcaption>ANGI sentiment and message volume December 20, 2024, as of 12:02 am ET | Source:&nbsp;Stocktwits</figcaption></figure>&nbsp;A watcher said the stock could be seeing a short squeeze amid insider buying; They projected it as a “breakout candidate” have the potential to rise to $5-$7.<stembedurl>https://stocktwits.com/cbinvb/message/597202948</stembedurl>The stock is down about 32% this year.reAlpha Tech Corp. ($AIRE)Dublin, Ohio-based reAlpha Tech, saw its shares jump 30.36% on Thursday after the real-estate technology company that commercializes artificial intelligence (AI)-powered technologies said its board approved an investment policy for the purchase of cryptocurrencies and to adopt Bitcoin (<a class="mention" data-mention="$BTC.X" data-symbol-id="BTC.X" href="https://stocktwits.com/symbol/BTC.X" target="_blank">$BTC.X</a>), Ethereum (<a class="mention" data-mention="$ETH.X" data-symbol-id="ETH.X" href="https://stocktwits.com/symbol/ETH.X" target="_blank">$ETH.X</a>) and Solana (<a class="mention" data-mention="$SOL.X" data-symbol-id="SOL.X" href="https://stocktwits.com/symbol/SOL.X" target="_blank">$SOL.X</a>) as primary treasury assets.Cryptocurrencies have been on a tear this year, with the upward momentum accelerating after Donald Trump’s victory in the presidential election. The incoming administration has come off as crypto-friendly, driving interest in digital currencies.Retail followers of reAlpha Tech stock on the Stocktwits platform continued to chat about it amid the news, with message volume spiking 1433%.One flagged the likelihood of the stock running up to the $2 area if it breaches the $1.53 resistance.&nbsp;<stembedurl>https://stocktwits.com/PLATINUM_TRADES/message/597300689</stembedurl>The stock has experienced a year-to-date loss of about 27%.My Size, Inc. ($MYSZ)Shares of My Size, an Israeli omnichannel e-commerce platform providing AI-driven software-as-a-service (SaaS) measurement solutions for e-commerce companies, jumped 20.54% on Thursday on nearly four times the average volume. The move came despite a lack of any meaningful catalysts.A retail watcher said he would buy the stock, citing the 500,000 float and warrants trading over $4.&nbsp;<stembedurl>https://stocktwits.com/JanF01/message/597220438</stembedurl>Message volume climbed 1,400 over 24 hours on Thursday.The stock is down a whopping 75% this year.TripAdvisor, Inc. ($TRIP)Needham, Massachusetts-based TripAdvisor, a travel guidance platform, came into retail’s radar after the company struck a merger arrangement with parent Liberty TripAdvisor Holdings, Inc. (<a class="mention" data-mention="$LTRPA" data-symbol-id="LTRPA" href="https://stocktwits.com/symbol/LTRPA" target="_blank">$LTRPA</a>) (<a class="mention" data-mention="$LTRPB" data-symbol-id="LTRPB" href="https://stocktwits.com/symbol/LTRPB" target="_blank">$LTRPB</a>). The merger allows TripAdvisor to acquire Liberty TripAdvisor for about $435 million. The transaction, scheduled to close in the second half of 2025, aims to simplify TripAdvisor’s capital structure and reduce its outstanding shares.The deal terms also allow TripAdvisor to retire nearly 27 million of its common stock currently held by Liberty TripAdvisor.<figure class="image"><img style="aspect-ratio:635/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/trip_sentiment_5f6140b626.png" alt="trip-sentiment.png" width="635" height="138"><figcaption>TRIP sentiment and message volume December 20, 2024, as of 12:02 am ET | Source:&nbsp;Stocktwits</figcaption></figure>The 24-hour message volume on TripAdvisor stock jumped 900% on Thursday. Sentiment toward the stock stayed ‘extremely bullish’ (84/100).For the year-to-period, the stock is down over 35%.ZenaTech, Inc. ($ZENA)ZenaTech is a&nbsp;Canada-based provider of AI drone solutions and enterprise SaaS solutions. The micro-cap's shares have been highly volatile amid deal announcements and the U.S. Federal Aviation Authority’s (FCC) clearance for visual line-of-sight commercial applications and data collection in the U.S., subject to specified conditions and limitations.Since its Oct. 1 listing, the stock has lost a little over 12%On Thursday, the stock soared 28.83% before ending at $7.73 on slightly above-average volume. The upside came following the company’s announcement that its subsidiary ZenaDrone has moved into its manufacturing facility in Phoneix, Arizona, to produce U.S. Defense and NATO drones as part of efforts to produce ‘Made in America’ drones.On Stocktwits, message volume spiked by 850% over the past 24 hours.Email newsroom[at]stocktwits[dot]com for updates and corrections.Read Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/3.ai-stock-falls-to-1-month-low-after-analyst-downgrades-to-sell/cJaY3nyRSL">c3.ai Stock Sinks To 1-Month Low On Analyst’s Sell Call: Retail Stays In Bearish Camp</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 06, 2024 in New York City as the market opened after the worst crash since 2022.

5 Technology And Communication Services Stocks With Heightened Activity On Stocktwits Thursday

On Thursday, a handful of stocks trading with notable losses for the year saw brisk activity on Stocktwits, with retail attention triggering a substantial upside. 

Equity

On Thursday, a handful of stocks trading with notable losses for the year saw brisk activity on Stocktwits, with retail attention triggering a substantial upside. 


Shares of Wolfspeed Inc. (<a class="mention" data-mention="$WOLF" data-symbol-id="WOLF" href="https://stocktwits.com/symbol/WOLF" target="_blank">$WOLF</a>), a prominent manufacturer of silicon carbide (SiC) semiconductors used in electric vehicles (EVs), surged over 20% on Friday, reaching one-week highs after significant insider buying boosted investor sentiment.SEC filings revealed that Wolfspeed directors collectively purchased shares worth approximately $817,000 this week. The purchases included notable buys from Interim CEO Thomas Werner, Duy-Loan Le, Stacy Smith, and Darren Jackson.That has helped counteract recent concerns over management changes and weaker financial performance.&nbsp;Earlier this week, Wolfspeed announced the sudden departure of CEO Gregg Lowe, prompting the board to begin a search for a permanent replacement.&nbsp;Financial challenges have also weighed on the stock, as the company earlier this month reported fiscal first-quarter revenue that missed expectations and issued second-quarter guidance well below estimates. The company also disclosed plans to reduce its workforce by 20% in an effort to streamline its cost structure.<figure class="image"><a href="https://stocktwits.com/symbol/WOLF"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WOLF_sentiment_meter_on_Nov_22_60f3f52b1c.png" alt="WOLF sentiment meter on Nov 22.png" width="1318" height="318"></a><figcaption>WOLF sentiment meter on Nov 22 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits has shifted dramatically, flipping from ‘extremely bearish’ to ‘extremely bullish’ by Friday afternoon, with message volume more than doubling over the past week.&nbsp;<stembedurl>https://stocktwits.com/Spaculatte/message/593686784</stembedurl><stembedurl>https://stocktwits.com/ianvollmer/message/593688085</stembedurl>On the platform, a poll reveals that 71% of retail investors believe it is the right to buy WOLF stock as the insider stock buys are bullish, while 13% believe it’s too risky and prefer staying out instead.Adding to the renewed enthusiasm, Roth MKM analyst Craig Irwin maintained a ‘Buy’ rating with a $20 price target after hosting meetings with Wolfspeed’s management.&nbsp;Irwin highlighted the company’s strategic importance as a U.S. leader in SiC semiconductor materials and noted that increased demand for 200mm SiC wafers could act as a significant catalyst for growth.Despite Friday’s rally, Wolfspeed shares remain down over 80% for the year, reflecting challenges such as the uncertain future of EV subsidies following Donald Trump’s election victory, which has raised concerns about SiC demand.&nbsp;Last month, the company captured investor attention after <a href="https://stocktwits.com/news-articles/markets/equity/wolf-stock-surges-on-chips-and-private-financing/cJcwCKRR4Y">saying</a> it was set to receive $750 million in U.S. government grants and an additional $750 million in financing led by Apollo Global Management to support its expansion efforts.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/estc-stock-rises-after-price-target-hikes-on-earnings-beat/cJIdG6uRg5">Elastic’s Stock Gets Flooded With Price Target Hikes After Earnings Beat: Retail Is All In</a>

Wolfspeed describes itself as “the world’s largest producer of silicon carbide technology."

Wolfspeed Stock Eyes Finishing Troubled Week Higher On Insider Buying Boost: Retail Regains Confidence  

Adding to the renewed enthusiasm, Roth MKM analyst Craig Irwin maintained a ‘Buy’ rating with a $20 price target after hosting meetings with Wolfspeed’s management.

Telehealth company Hims &amp; Hers Health Inc.’s ($HIMS) stock was up 2.4% in afternoon trading on Monday ahead of the company’s third-quarter earnings.Wall Street analysts expect Q3 earnings per share (EPS) to clock at $0.10 on revenue of $382.2 million. Wall Street is looking for signs of continuing demand for telehealth and wellness services. HIMS has beaten analyst estimates three times in the last four quarters.Retail sentiment on the stock turned ‘bullish’ (59/100) from ‘neutral’ (50/100) a week ago, while message volumes returned to the normal zone from low. &nbsp;<figure class="image"><img style="aspect-ratio:1304/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_05_at_12_03_32_AM_aab33ee228.png" alt="Screenshot 2024-11-05 at 12.03.32 AM.png" width="1304" height="306"><figcaption>HMS sentiment meter and message volumes on Nov 4 as of 1:35 pm ET</figcaption></figure>The company’s stock came under pressure recently after Eli Lilly posted a decline in GLP-1 revenue due to stock shortages and increasing competitive pressures, raising concerns about the sustainability of these medications that are also part of HIM’s offerings.Additionally, Hims &amp; Hers sells a compounded version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, as an alternative to those drugs. Should the FDA update its shortage list to exclude Novo Nordisk’s flagship drugs, Hims &amp; Hers will no longer be able to sell its version. That looming threat continues to weigh on the stock ahead of results, where investors hope management will provide additional color on the situation.In Q2, the company reported EPS of $0.06, beating estimates by nearly 43.78%. Its revenues stood at $315.65 million, 3.61% above estimates. Its subscribers in Q2 grew 43% to 1.9 million, compared to the previous year."Our second quarter results mark an acceleration in what was already an incredible trajectory. During the quarter, subscribers on our platform approached 1.9 million, increasing 43% year-over-year," Andrew Dudum, co-founder and CEO, said in a statement at the time.Some Stocktwits users were bullish on the prospects for the company’s stock.<stembedurl>https://stocktwits.com/Overstew/message/591085541</stembedurl>HIMS stock has more than doubled year-to-date.For updates and corrections, email newsroom@stocktwits.com

In Q2, the company reported EPS of $0.06, beating estimates by nearly 43.78%.| mImage source: Pixabay

Hims & Hers Stock Up Ahead of Earnings: Retail Sentiment Upbeat

Retail sentiment on the stock turned ‘bullish’ (59/100) from ‘neutral’ (50/100) a week ago, while message volumes returned to the normal zone from low. 

Shares of Wolfspeed, Inc. (<a class="mention" data-mention="$WOLF" data-symbol-id="WOLF" href="https://stocktwits.com/symbol/WOLF" target="_blank">$WOLF</a>), a leading manufacturer of chips primarily used in electric vehicles (EVs), surged over 25% on Tuesday after the company announced major funding news.Wolfspeed is set to receive $750 million in U.S. government grants and an additional $750 million in financing led by Apollo Global Management to support its expansion efforts.“Together these investments support Wolfspeed’s long-term growth plans and bolster domestic production of silicon carbide to power clean energy systems underpinning electric vehicles (EVs), artificial intelligence (AI) data centers, battery storage and more,” the company said in a statement.<figure class="image"><a href="https://stocktwits.com/symbol/WOLF"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_15_at_10_01_04_AM_68633fb576.png" alt="Screenshot 2024-10-15 at 10.01.04 AM.png" width="1314" height="320"></a><figcaption>WOLF sentiment and message volume Oct 15, as of 10:15 am ET | source: Stocktwits</figcaption></figure>WOLF quickly became the top-trending ticker on Stocktwits, with retail sentiment turning ‘extremely bullish’ as of 10 a.m. ET.<stembedurl>https://stocktwits.com/WALLSTMATADOR/message/588936538</stembedurl><stembedurl>https://stocktwits.com/Fullmoonblack/message/588944757</stembedurl>The company, which describes itself as “the world’s largest producer of silicon carbide technology,” counts major automakers like General Motors and Mercedes-Benz among its customers.“As a key player in the semiconductor industry, this proposed investment will enable us to solidify our leadership position with a first-of-its-kind 200mm silicon carbide manufacturing footprint in upstate New York and central North Carolina, while contributing to the resilience and competitiveness of the U.S. supply chain,” Wolfspeed CEO Gregg Lowe said.Wolfspeed has reportedly faced production challenges, especially at its chip plant in Mohawk Valley, New York, forcing it to rely on an older, more expensive facility.The company hasn’t posted an annual profit in over a decade, with its last quarter of positive net income in 2018, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2024-10-15/wolfspeed-wins-1-5-billion-in-financing-from-chips-act-apollo">Bloomberg</a>.The U.S. government’s $750 million grant stems from the 2022 CHIPS and Science Act, and will help cover part of Wolfspeed’s $6 billion-plus planned factory investments in North Carolina and New York.Additionally, Wolfspeed expects to receive around $1 billion in Section 48D cash tax refunds from the IRS over the coming years.WOLF stock remains down more than 60% year-to-date.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/wba-stock-rises-on-store-closure-plans/cJcwxPZR4n">WBA Stock Climbs On Plan To Close Thousands of Stores: Retail Is Betting On A Comeback</a>

Wolfspeed Grabs Retail Spotlight As Stock Rockets 25% On $1.5B Financing From US, Private Investors

The U.S. government’s $750 million grant stems from the 2022 CHIPS and Science Act, and will help cover part of Wolfspeed’s $6 billion-plus planned factory investments

IJS
iShares S&P Small-Cap 600 Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IJS News

IJSiShares S&P Small-Cap 600 Value ETF